USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
10 Nov 2022 | 03:45 PM GMT

Masterclass: Endpoints Selection in Clinical Trials for Digital Health Solutions

Anchored by:

Shaheen Lakhan
Chief Medical Officer
CLICK THERAPEUTICS

Participants:

Shaheen Lakhan Chief Medical OfficerClick Therapeutics
Shaheen Lakhan
Chief Medical OfficerClick Therapeutics
Chandana Fitzgerald President, CommunityHLTH
Chandana Fitzgerald
President, CommunityHLTH
Amit Shah Senior Finance Business Partner UKMCAstraZeneca
Amit Shah
Senior Finance Business Partner UKMCAstraZeneca
Bernhard Kappe Founder & CEOOrthogonal
Bernhard Kappe
Founder & CEOOrthogonal
Chris Cera CEOArcweb Technologies
Chris Cera
CEOArcweb Technologies
David Hohenschurz-Schmidt Research AssociateImperial College London
David Hohenschurz-Schmidt
Research AssociateImperial College London
NK
Nina Kiwit CEORoX Health
NK
Nina Kiwit
CEORoX Health
Patrick Fissler Co-Founder (Chief Scientific Officer)MindAhead
Patrick Fissler
Co-Founder (Chief Scientific Officer)MindAhead

About this Meeting

Proving clinical efficacy is one of the biggest challenges for SaMD manufacturers. However, it is key to getting buy-in from stakeholders. When designing a clinical trial for a digital health solution, selecting the right endpoints is very important to be commercially successful. How do I know what are the best endpoints for my product? What endpoints will help show the value to the different stakeholders?  

HealthXL members often ask these questions in our meetings, seeking advice and best practices in endpoint selection. For this reason, we are organizing this masterclass led by Shaheen E Lakhan, MD, PhD, FAAN (Chief Medical Officer, Click Therapeutics) to learn more about: 

  • Differences between objective/subjective, primary/secondary/exploratory, and health economics endpoints 
  • How do I know what are the best endpoints for my solution? How can digital health companies select and measure the right endpoints for their clinical trials? 
  • Aligning the endpoints selection with the commercial and regulatory strategies. What are the endpoints that will help them convince: 1) payers, 2) regulators, 3) physicians.  
  • How do the endpoints you collect depend on the stage of the product maturity?

We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.